Sarah Collins
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Sarah Collins
UNH Stock Up 4.1% on Solid Q3 2018 Results, View Up
UnitedHealth Group (UNH) released its Q3 2018 earnings today. UNH reported sales of $56.6 billion, up ~12.4% on a year-over-year basis.
Edwards Lifesciences’ Q3 2018 Earnings Estimates
Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
What to Expect of Edwards Lifesciences’ Q3 2018 Sales
Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.
Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results
Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.
Investor Insights: Teva Pharmaceutical’s Valuation Multiples
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.
Analysts Raised Their Recommendations on Teva Stock in October
Leerink raised its recommendation on Teva Pharmaceutical Industries from “underperform” to “market perform.”
Wall Street Analysts See Upside Potential of 3.9% in TEVA
Teva is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales.
ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.
Analysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
JNJ’s Consumer Business Expected to Be Driven by Innovation
Johnson & Johnson started shipments of its revamped baby care line in July, which is expected to register improved performance in the third quarter.
How Could JNJ’s Pharmaceuticals Business Perform in Q3 2018?
Tremfya reported sales of $126 million in the second quarter, compared to $72 million in sales reported in the first quarter.
UnitedHealth’s Optum Expectations for Q3 2018
Optum has been growing at a fast pace. It expects sales growth of ~19% CAGR (compound annual growth rate) from 2011 to 2018.
Analyst Ratings for UnitedHealth before Q3 2018 Earnings
Of the 24 analysts covering UNH stock, ten have recommended a “strong buy,” and 13 have recommended a “buy.”
What Triggered a 52-Week High for Boston Scientific in October?
On October 2, Morgan Stanley raised its target price for BSX stock. That day, BSX stock was trading at its 52-week high.
ABT Expands in Europe with Freestyle Libre 2 Approval
On October 1, ABT announced that it had received a CE mark in Europe for its next-generation continuous glucose monitoring system, the Freestyle Libre 2.
ABT Stock Registered a 52-Week High in October
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.
Jefferies Raised Its Target Price on UNH Stock: What’s the Outlook?
UnitedHealth Group (UNH) is one of the largest Fortune 500 companies.
Mylan Launches Its Generic Brevibloc Injection
Mylan announced the launch of its generic Brevibloc injection in single-dose bags on September 13.
Mylan’s Humira Biosimilar Opportunity in Europe
On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.
Mylan’s Recently Launched Generic Version of Ampyra
On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ Ampyra, which is used for improvement in walking for adults who have multiple sclerosis.
Wall Street Looks at Sales Forecasts for Mylan’s Fulphila
According to Leerink analyst Amy Fadia, Fulphila is expected to generate sales of $73.0 million in 2018. Fadia expects Fulphila’s sales to reach $260.0 million in 2019.
Align Technology Traded at Its 52-Week High in September
Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.
Wall Street Analysts Are Still Bullish on ALGN Stock
Align Technology (ALGN) stock hasn’t received any recommendation updates since the stock was upgraded by several analysts in July.
Wall Street Expects 24% Upside Potential for MYL Stock
On September 17, Leerink Partners raised its target price on Mylan (MYL) stock from $47.00 to $48.00.
ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain
On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.
Teva Announces First-to-File Launch of Generic Cialis
Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.
Jefferies Raises Target Price for BSX, Stock Rises
Today, Jefferies raised its target price for Boston Scientific (BSX) stock from $42 to $45. Let’s take a closer look.
Sanofi’s Organizational Restructuring: Investor Insights
On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.
Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials
Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.
Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent
On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.
A Look at Sanofi’s Valuation Multiples in September
On September 27, Sanofi (SNY) had a market capitalization of $113 billion, and its stock closed at $44.84.
Sanofi Stock Up 2.8% in September: What Lies Ahead?
On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.
Sanofi Stock: How Much Upside Potential Does Wall Street See?
In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.
High Valuation Multiples: Is EW Stock an Expensive Bet?
On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.
EW Stock Returned More than the S&P 500’s Gain in 2018
As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.
Analysts Continue to Be Cautious about Teva Stock
Teva Pharmaceutical Industries (TEVA) has seen a number of positive developments in the recent months, which have come as a sigh of relief for investors.
Teva Stock Was Down ~5.6% Yesterday and ~10.9% in the Last Week
On September 26, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $21.96, a decline of ~5.6% compared to the previous day’s closing price.
Abbott Laboratories Continues Its Bull Run with a Record High
On September 26, Abbott Laboratories (ABT) ended the trading day at $72.84, up ~0.89% from the previous day’s close.
Mylan Expands in the HIV Space, Partners with Atomo Diagnostics
Mylan (MYL) has exclusive commercialization rights to Atomo’s CE-marked self-test products in more than 100 countries.
Mylan’s Biosimilar of Neulasta Expected to Be a Key Growth Driver
Mylan (MYL) received FDA approval for Fulphila in June, and the drug was launched in the United States in July.
Wall Street Expects 9% Upside Potential for UnitedHealth Stock
As of September 24, ten of the 24 analysts covering UNH stock have given it a “strong buy” recommendation.
BSX Stock Nears 14-Year High, Up ~1.5% on FDA Eluvia Approval
Today, Boston Scientific (BSX) stock jumped on news of the FDA approval of its drug-eluting vascular stent system Eluvia for PAD (peripheral artery disease) treatment.
Why ABT Stock Is Trading at a Record High Today
Today, Abbott Laboratories (ABT) opened trading ~2.9% higher than the previous trading day’s closing price of $68.79.
Opportunities and Competition for J&J’s Blockbuster Drug, Xarelto
Xarelto is a blood thinner developed and commercialized by Johnson & Johnson’s (JNJ) subsidiary, Janssen, and Bayer (BAYZF).
Market Opportunities for J&J’s Depression Drug, Esketamine
This month, Johnson & Johnson’s (JNJ) subsidiary, Janssen, submitted a new drug application for its esketamine nasal spray for treatment-resistant depression in adults.
How J&J Has Expanded Its Orthopedics Business
Johnson & Johnson is focused on strengthening its medical device technologies business.
Is Abbott Laboratories Trading at a High Valuation in September?
Abbott stock has been gaining momentum recently, and its valuation has improved.
Abbott Laboratories’ 379th Consecutive Quarterly Dividend
On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15.
ABT Returns Almost Double the S&P 500’s Year-to-Date Gain
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).
Abbott Laboratories Stock Trades at Its 52-Week High in September
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.
Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.
Hologic’s Cynosure Headwinds Could Impact 2018 Earnings
On September 12, Hologic (HOLX) provided an update on the financial impact of the suspension of its marketing and distribution of the company’s Vitalia handpieces and probes.
A Look at Hologic Stock’s Recent Performance
Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.
Why Tandem Diabetes Care Stock Is Crashing Today
The rating downgrade from Baird on September 14 triggered the downward trend in Tandem stock.
Competition Dynamics for Ajovy—Teva’s Migraine Drug
Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.
Analysts Raise Their Recommendations on BSX Stock in September
On September 14, Reuters surveyed 24 analysts covering BSX stock. Of these analysts, 21 analysts gave a “buy” or “strong buy” recommendation on the stock.
Boston Scientific’s Ninth Acquisition of 2018: Augmenix
With the acquisition of Aegmenix, Boston Scientific adds its SpaceOAR system to its men’s health portfolio, which is part of BSX’s MedSurg segment.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
Boston Scientific Stock in the Week Ended September 14
Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.
Jefferies Raised Its Recommendation on BSX Stock
Jefferies expects Boston Scientific to report EPS of $1.60 in fiscal 2019, $1.82 in fiscal 2020, $2.09 in fiscal 2021, and $2.34 in fiscal 2022.
Why Is BSX Stock Trading at Its 14-Year High Today?
Today, Boston Scientific (BSX) opened at $37.11, up ~1.8% since yesterday. This is the highest level for BSX stock since October 2004.
Johnson & Johnson Seeks EU and US Label Expansion for Darzalex
Johnson & Johnson’s (JNJ) subsidiary Janssen Pharmaceuticals filed regulatory submissions for label expansion of its multiple myeloma drug Darzalex.
Johnson & Johnson: Analyst Recommendations and Target Price
Over the last month, JNJ stock has generated increased interest due to some key product approvals and trial data announcements.
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
Hologic Stock Down ~9% Year-to-Date
On September 6, Hologic (HOLX) ended the day at $38.74.
UnitedHealth Group Goes Ex-Dividend Today
UnitedHealth Group (UNH) has announced that its board of directors has authorized a cash dividend of $0.90 per share.
Analysts Raise Target Prices on UNH Stock in September
Of the 23 analysts covering UNH stock, all of them have “buy” or “strong buy” recommendations for UnitedHealth Group.
UnitedHealth Group Stock at 52-Week High, Up 22% Year-to-Date
UnitedHealth Group (UNH) stock registered its 52-week high of $270.17 last week on August 30.
Why Sangamo Therapeutics Stock Is Down More than 22% Today
Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.
Sanofi Gets European Approval for Ablynx’s Caplacizumab
On September 3, Sanofi announced that it has been granted authorization by the European Commission for Cablivi (caplacizumab).
Wall Street Analysts See an Upside of ~9% in SYK Stock
On August 31, Stryker had a consensus 12-month target price of $184.43 per share.
Why Analysts Raised Their Target Prices on WMGI Stock in August
On August 31, Wright Medical Group had a consensus 12-month target price of $32.07 per share.
Wall Street Recommendations, Target Price for K2M Group Holdings
On August 30, Needham had cut its recommendation on KTWO stock from “buy” to “hold.”
Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday
Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.
Why Teva’s Generic EpiPen Contribution Could Be Modest in 2018
Teva Pharmaceutical Industries (TEVA) received FDA (U.S. Food and Drug Administration) approval for its generic version of Mylan’s EpiPen.
Teva Stock Continues to Trend Higher on Positive News
Teva Pharmaceutical Industries (TEVA) has risen ~9% over the last five days.
Berkshire Hathaway Increased Its Stake in Teva Again
Teva stock has gained ~27.0% year-to-date on the back of the positive news that included product launches and study data.
Non-Opioid Pain Therapy Market Opportunity for Teva
The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.
What Analysts Recommend for Array BioPharma Stock
As of August 15, analysts’ target price for ARRY is $23.57, which implies a ~71.7% return over the next 12 months based on the stock’s August 14 price of $13.73.
FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr.
Array BioPharma Missed Sales Estimates for Q4 2018
Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million.
What You Need to Know about Mylan’s Strategic Review Announcement
Mylan announced that it created a strategic review committee for the evaluation of “a wide range of alternatives to unlock the true value of our one-of-a-kind platform.”
Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.
Mylan’s Morgantown Restructuring and Remediation Program
Mylan’s Morgantown restructuring and remediation program comprises discontinuing certain products on the basis of profitability, market competition, and pricing dynamics.
Mylan’s North America Sales Down 22% in Q2 2018: What’s Next?
In Q2 2018, Mylan (MYL) reported North America segment net sales of $1.0 billion, which represented a YoY decline of ~22%.
MYL Stock Down ~3% since Its Q2 2018 Results on August 8
The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion.
Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
Mylan (MYL) reported its Q2 earnings on August 8. On August 13, 13 of 20 surveyed firms still held a “buy” or “strong buy” rating on MYL.
Mylan Launches First Adcirca Generic, Stock Moves Up
Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States.
RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDP, AKRX
RBC Capital Markets issued a report highlighting its bullish stance on the generic pharma industry, which is under immense pricing pressure.
Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.
Boston Scientific Stock Up Today on the Acquisition of Veniti
Boston Scientific (BSX) announced the acquisition of Veniti for $108.0 million. BSX already owns a 25% stake in Veniti.
Teva’s Granix Gets FDA Approval for Expanded Indication
Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.
BSX’s Cardiovascular Business Stays Strong
In Q2 2018, Boston Scientific’s (BSX) Cardiovascular sales grew 10% YoY (year-over-year) to $965 million, and it saw ~8% operational growth in the Cardiovascular business.
What’s Driving BSX’s Cardiac Rhythm Management Business
In Q2 2018, Boston Scientific’s (BSX) CRM (cardiac rhythm management) sales rose ~3% YoY (year-over-year) to $494 million.
What Are the Key Drivers of BSX’s MedSurg Business?
In Q2 2018, Boston Scientific’s (BSX) MedSurg sales grew ~10.4% YoY (year-over-year) to $751 billion, contributing ~30% of the company’s total sales.
Illumina Stock Trades at Record High on Stellar Q2 2018 Results
Yesterday, after the market closed, Illumina (ILMN) announced its Q2 2018 earnings results.
The Majority of Analysts Recommend a ‘Hold’ for Teva
Teva Pharmaceutical Industries (TEVA) plans to release its second-quarter earnings results on August 2.
How the Freestyle Libre CGM Opportunity Is Playing Out for ABT
Abbott Laboratories stated during its second-quarter earnings release that it’s on track for achieving its fiscal 2018 guidance for Libre.
Abbott Laboratories’ Stock Price Performance in July
Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.
Seattle Genetics Increased Its Fiscal 2018 Outlook
During the second-quarter earnings release, Seattle Genetics provided an increased guidance range for its fiscal collaboration sales.